Basic Eldepryl Information

• INN (International Nonproprietary Name): Selegiline (also known as Selegilina, Selegilinum, L‑Deprenalin).
• Brand Names Available In Canada (English): not specified.
• ATC Code: N04BD01 — Monoamine Oxidase B Inhibitors (anti‑parkinson drugs).
• Forms & Dosages: Tablets 5 mg and 10 mg; capsules 5 mg; orally disintegrating tablet 1.25 mg (Zelapar); transdermal patch 6, 9, 12 mg/24 hr (Emsam).
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): not specified.
• OTC / Rx Classification: Prescription only (Rx) in most jurisdictions.

Latest Research Highlights

Patients and clinicians want to know: how much symptom relief can MAO‑B inhibitors realistically provide?

Recent systematic reviews and randomized trials from 2022–2025 report that MAO‑B inhibitors offer modest symptomatic benefit for Parkinson’s disease, most noticeably when used as adjuncts to levodopa to reduce “wearing‑off” and off‑time.

Canadian observational cohorts (2022–2024) tracking older adults reported functional outcomes and adverse events that align with international findings: clinical benefit is small‑to‑moderate and tolerability is generally acceptable.

Neuroprotective claims remain unproven in humans; there is no definitive evidence that selegiline slows disease progression in clinical trials over standard care.

Canadian clinicians favour clear, realistic conversations about the small‑to‑moderate benefits and the tradeoffs linked to side effects when discussing selegiline or other MAO‑B agents.

Bilingual consent materials are useful for shared decision‑making, especially in bilingual and Indigenous settings.

Rural patients often report delayed access to neurology specialists, which increases the importance of primary‑care and pharmacy involvement in treatment planning.

• Recommended Reading For Clinicians: recent systematic reviews and national Parkinson’s management summaries (2022–2025).
• Suggested Article For Teams: comparative safety profiles of selegiline vs rasagiline and safinamide.

Clinical Effectiveness In Canada

Many clinicians want clear guidance on whether selegiline improves motor control in Canadian practice.

Health‑system analyses within Canada indicate that selegiline as an adjunct to levodopa can reduce motor fluctuations in early‑to‑moderate Parkinson’s disease compared with levodopa alone, though the magnitude of benefit varies across cohorts.

Real‑world Canadian data note adherence and side‑effect profiles that mirror international reports, with common mild adverse effects such as nausea and dizziness and rarer events like orthostatic hypotension.

Health Canada monographs and clinical reviews recommend monitoring when selegiline is used with dopaminergic polytherapy.

• Monitoring Checkpoints: blood pressure and orthostatic vitals, psychiatric symptoms (hallucinations, agitation), review of concomitant serotonergic drugs, and liver function monitoring if clinically indicated.

Multidisciplinary care is important, particularly for remote Indigenous and rural communities where neurologist access is limited and pharmacists and primary care must share management responsibilities.

Indications And Expanded Uses

Patients often ask whether selegiline can help mood as well as movement.

Approved Indication

Adjunctive treatment for Parkinson’s disease; monotherapy in early Parkinson’s in some labels.

Off‑Label/Experimental

Transdermal preparations (Emsam) are approved in other jurisdictions for depression, but oral selegiline brands like Eldepryl are not typically indicated for depression in Parkinson’s‑oriented products and strong Canadian RCT evidence for antidepressant use with oral selegiline is limited.

• Common Approved Scenarios: adjunct to levodopa/carbidopa for wearing‑off in Parkinson’s disease.
• Common Off‑Label Scenarios: specialist‑led mood disorder trials or investigational uses with documented rationale and informed consent.
• Off‑Label Monitoring: document rationale, obtain informed consent, monitor psychiatric status, and reconcile medications carefully.

Prescribers should note that brand and formulation matter: tablets, capsules, and ODTs are the Parkinson’s‑oriented products; patches such as Emsam are a different formulation with different labeled uses.

Provincial drug plan policies typically restrict coverage to labeled indications, so documenting clinical need is essential for approval and reimbursement applications.

Composition And Brand Landscape

Patients frequently ask which brands they might receive and whether generics are available.

The INN is Selegiline, and common brand names appearing in supplier registries include Eldepryl and Zelapar (ODT), with global brands such as Emsam for transdermal use.

Form strengths available include 5 mg and 10 mg tablets, 5 mg capsules, 1.25 mg ODT, and transdermal patches in 6/9/12 mg per 24 hours.

Competitive manufacturers listed in supplier registries include Somerset, Valeant, Mylan, Sun Pharma, Teva, and Sandoz; always verify current suppliers through official wholesale listings.

• Steps To Verify Brand Versus Generic: check the DIN on the prescription, confirm packaging and manufacturer on the product, and contact the wholesaler if stock is uncertain.

Major Canadian pharmacy chains like Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs commonly stock antiparkinson agents, but stock levels and brand availability vary by region.

Contraindications And Special Precautions

Safety is a top concern for patients starting an MAO‑B inhibitor.

Absolute contraindications listed in product information include hypersensitivity to selegiline, concurrent use with other MAOIs, certain opioids such as meperidine, serotonergic agents (risk of serotonin syndrome), and pheochromocytoma (risk of hypertensive crisis).

Relative contraindications that require closer monitoring include peptic ulcer disease, severe cardiovascular disease, psychosis or mania, and diets high in tyramine.

• Absolute Contraindications: hypersensitivity to selegiline or excipients; concomitant MAOIs; meperidine; serotonergic agents; pheochromocytoma.
• Relative Contraindications: history of peptic ulcer disease; severe hypertension or arrhythmias; psychosis/mania; high‑tyramine diets.

Pharmacists should perform medication reconciliation at every refill and provide bilingual adverse‑effect counselling.

Monitoring suggestions include regular blood pressure checks (including orthostatic readings), mental‑status screening for hallucinations or agitation, and liver function tests if indicated.

Dosage Guidelines

Patients commonly ask how to take Eldepryl safely and when dose changes are needed.

Standard adult dosing for Parkinson’s disease is 5–10 mg daily, often given as 5 mg twice daily for tablets or capsules, and ODT dosing usually 1.25–2.5 mg once daily.

Clinical guidance advises starting at the lower end of dosing for elderly patients and titrating cautiously, with dose adjustments in hepatic impairment.

• Titration Steps: start at 5 mg or 1.25 mg ODT, reassess motor fluctuations and side effects after 1–2 weeks, increase cautiously if needed.
• Monitoring Intervals: check blood pressure and mental status on initiation and after dose changes; review concomitant drugs when adding to levodopa/carbidopa.

Practical patient advice: align dosing with levodopa schedules to reduce wearing‑off and provide bilingual written dosing schedules at dispensing.

Provincial formularies may impose dosing limits or require prior authorisation; check ODB, BC PharmaCare, and RAMQ before dispensing large quantities.

Interactions Overview

Drug and food interactions are the reason many patients worry about MAO‑B therapy.

Selegiline interacts with other MAOIs, certain opioids (notably meperidine), and serotonergic medications such as SSRIs and SNRIs, carrying a risk of serotonin syndrome.

Tyramine‑rich foods can precipitate hypertensive crises per regulatory labelling, though oral MAO‑B selectivity reduces risk compared with non‑selective MAOIs at Parkinson’s doses.

• Immediate Red Flags For Patients: sudden severe headache, neck stiffness, profuse sweating, rapid heartbeat — seek urgent medical care.
• Pharmacist Actions: verify full medication list, counsel on food choices, and advise patients not to import OTC drugs without checking.

Common Canadian foods to warn about include aged cheeses used in poutine variations and certain cured meats and fermented products; practical substitution guidance helps adherence.

Cultural Perceptions And Patient Habits

Many patients describe worry about dietary limits and stigma around Parkinson’s disease.

Online forums and support groups show patients appreciate symptom control from MAO‑B inhibitors but worry about interaction rules and polypharmacy.

Canadians value equitable drug access and clear bilingual information; culturally safe communication is important for Indigenous and Francophone communities.

• Patient Education Touchpoints: explain side effects plainly, review food interactions, perform medication reconciliation, and provide bilingual materials.
• Access Mitigation: community education sessions and telehealth can help rural patients who face specialist wait times and variable pharmacy stock.

Local pharmacy relationships with chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs influence refill reliability and counselling availability in many communities.

Availability And Pricing Patterns

Patients often ask whether eldepryl is easy to get and how much it will cost.

Multiple formulations exist worldwide, but Canadian availability and pricing depend on suppliers, Health Canada listings, and provincial formularies.

Major retail pharmacies may stock antiparkinson agents, but inventory and brand availability vary regionally; online Canadian pharmacies may offer access but require valid prescriptions.

In our online pharmacy, eldepryl is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

• Steps To Check Coverage: confirm the DIN on the product, call provincial drug plan (ODB, BC PharmaCare, RAMQ) for listing status, and contact your pharmacy chain for stock.
• Cross‑Border Note: US prices can be lower for some branded products, but cross‑border importing raises legal and safety issues and should be discussed with a pharmacist.

Comparable Medicines And Preferences

Clinicians and patients weigh alternatives based on dosing convenience, interactions, and formularies.

Relevant alternatives include rasagiline and safinamide in the MAO‑B class, and COMT inhibitors such as entacapone for adjunctive wearing‑off control.

Comparative points: rasagiline is once‑daily and newer; safinamide is a reversible MAO‑B inhibitor and has a different side‑effect profile; COMT inhibitors address levodopa wearing‑off by different mechanisms.

• Pros & Cons Checklist: selegiline — established use and multiple forms; rasagiline — once‑daily dosing; safinamide — reversible MAO‑B with specific adjunct indications; COMT inhibitors — effective for levodopa extension but different interaction profiles.

Choice in Canada is often driven by DIN availability, provincial formulary listings, patient lifestyle (meal patterns, travel), and tolerance for dietary advice.

Pharmacists should review comorbidities and concomitant medications when counselling on alternatives to eldepryl.

FAQ Section

Here are quick answers to common patient questions seen in Canadian practice.

Q: Can I take Eldepryl with my SSRI?

A: Generally no — the combination risks serotonin syndrome and requires specialist or pharmacist guidance and an appropriate washout period before switching.

Q: Will selegiline be on my provincial drug plan?

A: Coverage varies by province and formulation; check Ontario Drug Benefit, BC PharmaCare, or RAMQ and have the DIN ready for a coverage check.

Q: Are dietary restrictions strict with selegiline?

A: At Parkinson’s dosing, oral MAO‑B inhibitors have a lower tyramine risk than non‑selective MAOIs, but patients should avoid large amounts of aged or fermented foods and seek clinician advice if concerned.

Q: Can I travel to the US to buy cheaper Eldepryl?

A: Cross‑border purchases can involve legal and safety considerations; consult a pharmacist and your provincial drug plan before considering imports.

• Quick Actions: call your pharmacy for DIN and stock, tell your specialist about any change, and keep an updated medication list for the pharmacist.

Guidelines For Proper Use

Proper use reduces risk and improves benefit from MAO‑B therapy.

Best practices include confirming the indication, reconciling all medications, counselling on interactions and diet, and documenting monitoring plans in the patient record.

Pharmacist Checklist At Dispensing: verify DIN and product form, confirm prior authorisation with provincial plans if required, provide bilingual written instructions, review OTC meds and diet, and schedule follow‑ups.

Missed Dose

Take the missed dose as soon as you remember unless it is nearly time for the next dose; do not double up doses.

Overdose

Seek emergency care immediately; overdose may cause severe hypertension, agitation, convulsions, or hallucinations.

• Storage: keep in original packaging at room temperature below 25°C, protected from moisture and light, and out of reach of children.
• Rural/Indigenous Settings: coordinate care with local health centres, use telepharmacy for counselling, and prepare multi‑disciplinary plans for follow‑up.

Delivery Across Canada (English)